Ticagrelor-induced acute kidney injury can increase serum concentration of statin and lead to concurrence of rhabdomyolysis

Park, In Seong; Lee, Soo Bong; Song, Sang Heon; Seong, Eun Young; Kim, Il Young; Rhee, Harin; Kim, Min Jeong; Lee, Jun Young

doi:10.14744/anatoljcardiol.2017.8200

Cited by 8 publications

(13 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…A review of literature revealed eleven [14][15][16][17][18][19][20][21][22][23][24] reported cases of ticagrelor induced ARF and rhabdomyolysis (Table 1). 10 cases were found in patients who were also on prescription of high intensity statins with rosuvastatin being the most commonly used statin.…”

Section: Discussionmentioning

confidence: 99%

Ticagrelor and Statin Interaction Induces Rhabdomyolysis and Acute Renal Failure: Case reports and Scoping Review

Kariyanna

Haseeb

Chowdhury

et al. 2019

AJMCR

View full text Add to dashboard Cite

Ever since evidence about the increased risk of stent thrombosis with drug eluting stents (DES) surfaced in 2005, the Food and Drug Administration (FDA) has recommended the use of dual antiplatelet therapy (aspirin with P2Y12 inhibitor) following DES placement. The PLATO trial demonstrated lower mortality rates with the use of Ticagrelor when compared to clopidogrel (9.8% vs. 11.7%, p<0.001) when treating patients with acute coronary syndrome. Given their pleiotropic benefits, statins are today the second most prescribed drug in the United States and often co-prescribed with Ticagrelor. FDA's post market surveillance of Ticagrelor use along with statins in post-myocardial infarction care is now revealing novel and serious adverse events. We present two cases of rhabdomyolysis and acute renal failure (ARF) which develop while the patients were on statins and Ticagrelor. Case 1: A 66-year-old female presented with bilateral thigh pain for 3 days. One month prior to presentation, she was managed for non-ST segment elevation myocardial infarction (NSTEMI) and had been started on aspirin, ticagrelor and simvastatin. Laboratory values revealed creatinine kinase (CK) level at 40,000 U/L and creatinine 3.2 mg/dL suggesting rhabdomyolysis and ARF. Case 2: A 63-year-old male presented with generalized body aches and fatigue for 4 days. He had sustained STEMI two months before and received two drug eluting stents (DES) and aspirin, ticagrelor and rosuvastatin had been initiated. CK was 380,000 U/L and creatinine 7.94 mg/dL suggesting rhabdomyolysis and ARF. Both patients presented with rhabdomyolysis and acute renal failure within weeks after ticagrelor and statin were commenced. A review of the literature indicated that 11 similar cases of ticagrelor-induced ARF and rhabdomyolysis had been reported. Ticagrelor competes with statins when metabolized by cytochrome P450 (CYP) 3A4 leading to statin retention, leading to major adverse effects like rhabdomyolysis and acute renal failure. Our review is intended to alert clinicians about this important drug interaction.

show abstract

Section: Discussionmentioning

confidence: 99%

Ticagrelor and Statin Interaction Induces Rhabdomyolysis and Acute Renal Failure: Case reports and Scoping Review

Kariyanna

Haseeb

Chowdhury

et al. 2019

AJMCR

View full text Add to dashboard Cite

show abstract

“…3,9 Rosuvastatin, considered the most potent statin, [18][19][20] is more likely to cause rhabdomyolysis than atorvastatin, simvastatin, or pravastatin. 3,21 Other factors increasing the risk of statininduced rhabdomyolysis include statin dose, age, female gender, low body mass index, and untreated or uncontrolled hypothyroidism. 1,3,4,22 On the contrary, ticagrelor, a direct-acting oral antiplatelet drug approved in 2011, 1,3 is not known to cause myotoxicity.…”

Section: Discussionmentioning

confidence: 99%

“…Only upon review of 2 case reports in the literature was ticagrelor discontinued on hospital day 7, resulting in normalization of CPK and complete recovery. 7 In a case reported by Park et al, 21 all of the patient's home medications (including rosuvastatin) were discontinued upon hospital admission, except ticagrelor and aspirin. However, the patient's rhabdomyolysis only resolved upon changing ticagrelor to clopidogrel on hospital day 6.…”

Section: Discussionmentioning

confidence: 99%

The Interaction Between Rosuvastatin and Ticagrelor Leading to Rhabdomyolysis: A Case Report and Narrative Review

2020

View full text Add to dashboard Cite

Objective: Drug interactions are a common cause of morbidity and mortality and may require prompt discontinuation of therapeutic regimens due to harmful side effects. Patients with acute coronary syndromes are likely to be prescribed multiple medications that are metabolized through the cytochrome P450 system, increasing the probability for drug interaction. Atorvastatin and simvastatin are both well known to interact with the oral P2Y12 agent ticagrelor. The purpose of this paper is to describe the interaction of ticagrelor with rosuvastatin leading to rhabdomyolysis, which is less clearly defined in the literature. Method: We report a case of a 74-year-old male who presented with bilateral lower extremity weakness and difficulty ambulating for one month after being prescribed ticagrelor for a drug eluting stent, in the setting of already being on rosuvastatin. His clinical picture and laboratory findings were consistent with a diagnosis of rhabdomyolysis. His medications were adjusted to a regimen of clopidogrel and alirocumab. One month later, he returned to his baseline status. Results: The mechanism of interaction between rosuvastatin and ticagrelor appears to be multifactorial. It may be caused by CYP450-mediated metabolism from a small amount of crossover between isoenzymes. Ticagrelor may also cause acute kidney injury, increasing the concentration of rosuvastatin. Other mechanisms of interaction include genetic differences in the organic anion transporter polypeptides and transportation through p-glycoprotein. Conclusion: Future pharmacokinetic studies are warranted to better understand the interaction.

show abstract

“…Несмотря на очевидные преимущества комбинированной антиагрегантной и гиполипидемической терапии, возможное взаимодействие между статинами и тикагрелором может привести к миопатии и рабдомиолизу [8][9][10][11][12][13][14][15][16][17]. В обзорной статье P.T.…”

Section: Rosuvastatin Ticagrelor and The Risk Of Rhabdomyolysisunclassified

“…В настоящее время имеется ряд публикаций о клинических случаях рабдомиолиза у пациентов, одновременно принимающих после ЧКВ широко используемые статины (розувастатин, аторвастатин, симвастатин) и антитромбоцитарный препарат тикагрелор [8][9][10][11][12][13][14][15][16][17].…”

Section: Introductionunclassified

The Problem of Drug Interactions Between Rosuvastatin and Ticagrelor in the Aspect of the Risk of Rhabdomyolysis: Discussion of the Problem and Description of the Clinical Case

Gaisenok¹,

Chichkov²,

Леонова³

2022

Racionalʹnaâ farmakoterapiâ v kardiologii

View full text Add to dashboard Cite

Background. Combination therapy with two antiplatelet agents (ticagrelor or clopidogrel plus acetylsalicylic acid) and a high dose statin is recommended in accordance with clinical guidelines for patients undergoing acute coronary syndrome and coronary intervention. Combined therapeutic regimens have drug-drug interaction potential. Rhabdomyolysis is a known side effect of statin therapy, and there is evidence that co-therapy with ticagrelor increases the risk of this complication.Case description. A 72-year-old female patient was hospitalized with typical signs of rhabdomyolysis: muscle pain, oliguria, weakness, significant increases in creatine kinase (CK), myoglobin and creatinine. One month before that, she was urgently hospitalized with acute recurrent ST-elevation myocardial infarction and underwent endovascular intervention on a critical stenosis of the left anterior descending artery with stent implantation. After that, rosuvastatin 40 mg per day and ticagrelor 90mg 2 times a day were added to her therapy. During the current hospitalization, rosuvastatin, ACE inhibitors and spirolactone were canceled, infusion therapy was carried out, which led to a rapid regression of symptoms, restoration of adequate diuresis, and normalization of CK, myoglobin and creatinine levels. Conclusions. The combined use of ticagrelor with rosuvastatin (especially at a high dose) increases the risk of rhabdomyolysis in elderly patients. Patients taking ticagrelor may require changes in statin therapy, dose adjustments, and possible drug changes to avoid pharmacological interactions and an increased risk of side effects.

show abstract

Ticagrelor-induced acute kidney injury can increase serum concentration of statin and lead to concurrence of rhabdomyolysis

Cited by 8 publications

References 8 publications

Ticagrelor and Statin Interaction Induces Rhabdomyolysis and Acute Renal Failure: Case reports and Scoping Review

Ticagrelor and Statin Interaction Induces Rhabdomyolysis and Acute Renal Failure: Case reports and Scoping Review

The Interaction Between Rosuvastatin and Ticagrelor Leading to Rhabdomyolysis: A Case Report and Narrative Review

The Problem of Drug Interactions Between Rosuvastatin and Ticagrelor in the Aspect of the Risk of Rhabdomyolysis: Discussion of the Problem and Description of the Clinical Case

Contact Info

Product

Resources

About